Diabetes

The study presented at the ADA Scientific Sessions found that raising out-of-pocket costs for diabetics with Medicare could reduce adherence and ultimately raise healthcare spending.

Younger patients and those who have been diagnosed less than 5 years are less likely to follow guidelines for regular eye exams, despite the risk of blindness.

The shift in care for those with diabetes is about new payment models and a change in mindset, said the speakers, including Robert A. Gabbay, MD, PhD, of Joslin Diabetes Center.

A matchstick-like device provides continuous delivery of exenatide, producing dramatic reductions in A1C levels.

The study evaluated the 3 new anti-VEGF agents for treatment of a condition that frequently occurs in patients who suffer from diabetes mellitus.

A study published in the American Journal of Preventive Medicine shows that grip strength of young, healthy adults could prove useful in the diagnosis of diabetes and hypertension.

The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.

Measure definitions to estimate the effects of cost sharing on adherence to medications prescribed together (ie, concurrent adherence) are lacking.

Middle-age men especially were more likely to have undiagnosed diabetes if they suffered from erectile dysfunction, according to the study.

The combination involves long-acting insulin and a GLP-1 receptor agonist.

From 2015 AACC: Fingernail clippings could replace blood draws for diabetes tests, and a new biomarker could speed up tests for gestational diabetes.

Health plans and pharmacy benefits managers are expected to scrutinize the FDA approval to ensure that only those patients who truly need the drug get it.Drugmakers say discounts will cause the price to fall below the $14,600 annual wholesale price listed.

The Sanofi and Regeneron therapy, to be marketed as Praluent, was among the most-anticipated FDA approvals of the year. Late-day reports put pricing at $40 a day wholesale, well above estimates, although insurers will seek discounts.

The authors undertook a literature search on treatment intensification in diabetes care to identify relevant research that has been published since 2000.

The proposal marks the latest attempt to give consumers more information about the foods they consume.

CMS' shift to value-based payments has also shifted diabetes care models from cost-centered systems to cost-savings centers, according to Robert A. Gabbay, MD, PhD, chief medical officer and senior vice president of Joslin Diabetes Center.

The study has policy implications since Americans 65 and older are eligible for Medicare, and trustees reported this week that the hospital fund will only be solvent until 2030.

Kerri Sparling, writer/editor at patient diabetes blog Six Until Me, knows from experience the importance of having a community support system when dealing with a chronic illness like diabetes.

The findings have policy importance in the developing world, where low birth weight is often followed by rapid transition to Western lifestyles.

Data from mHealth can inform, assess, anticipate, and aid in interventions while monitoring and coordinating patient health status and care.

The results will not wipe out a recent $2.37 billion settlement reached in about 9000 bladder cancer claims involving the drug.

Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.

Managing diabetes is about more than just blood-sugar elevation; discussions about management should go beyond medication adherence to include how the disease affects a patient's life, explains Andrew Pumerantz, DO, FACP.

In a pattern repeated among those who gained insurance on the Marketplace exchanges, it's clear the uninsured had more pent-up medical needs than policymakers realized.